Do We Need Maintenance with Anti-CD20 Antibody after First-Line Therapy for All Newly Diagnosed Follicular Lymphoma Patients?

Follicular lymphoma (FL) is one of the most common subtypes of lymphoma in Western countries, accounting for 10-20% of all newly diagnosed non-Hodgkin’s lymphomas. Clinical course of FL is typically indolent, with impressive responses to initial treatments. Nevertheless, frequent relapses with shorter remission duration occur that need additional therapeutic interventions and increase the risk of drug resistance.